Results 131 to 140 of about 41,093 (223)

Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness [PDF]

To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a
Ruth Levine, Jean Lee, Michael R. Kremer, Georg Weizsacker, Heidi Williams, Ernst R. Berndt, Rachel Glennerster   +6 more
core  

A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila

, 2014
Development of effective malaria vaccines is hampered by the problem of producing correctly folded Plasmodium proteins for use as vaccine components.
David R. Cavanagh, Hartmann Marcus W. W., Eleni-Muus Janna, Graeme J M Cowan, Ingo Aldag, Hartmann, Marcus W W, Samuel, Kay, Aldag Ingo, Samuel Kay, Alison M Creasey, Bockau, Ulrike, Cavanagh, David R, Alison M. Creasey, Creasey Alison M., Eleni-Muus, Janna, Cavanagh David R., Graeme J. M. Cowan, Cowan, Graeme J M; id_orcid, Ulrike Bockau, David R Cavanagh, Creasey, Alison M, Kay Samuel, Cowan Graeme J. M., Aldag, Ingo, Janna Eleni-Muus, Marcus W. W. Hartmann, Marcus W W Hartmann, Bockau Ulrike   +27 more
core   +1 more source

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination : a phase 3 randomized, controlled trial in children and young infants at 11 African sites [PDF]

, 2014
A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission.; 6,537 ...
RTS, S. Clinical Trials Partnership, RTS,S Clinical Trials Partnership, The RTS,S Clinical Trials Partnership (2014) (614272)   +2 more
core   +1 more source

Efficacy and immunogenicity of RTS,S/AS01 and R21/Matrix-M malaria vaccines: - Systematic review and meta-analysis

Journal of Infection and Public Health
Background: Malaria is one of the most concerning issues of public health. Despite efforts in vector control and chemoprevention, it continues to remain a burden, and hence, a vaccine for malaria has the potential to reduce the overall parasite reservoir.
Hafsah Asjad, Muhammad Wahhaab Sadiq, Saba Siddiqui, Sarosh Sherali, Muhammad Tahir Yousafzai, Shafaq Taseen, Farah Naz Qamar   +6 more
doaj   +1 more source

Creating Markets for New Vaccines Part II: Design Issues [PDF]

Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed.
Michael Kremer
core  

Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan

Human Vaccines & Immunotherapeutics, 2017
Although vaccines would be the ideal tool for control, prevention, elimination, and eradication of many infectious diseases, developing of parasites vaccines such as malaria vaccine is very complex.
Shima Mahmoudi, Hossein Keshavarz
doaj   +1 more source

Malaria eradication and elimination: views on how to translate a vision into reality

, 2015
Although global efforts in the past decade have halved the number of deaths due to malaria, there are still an estimated 219 million cases of malaria a year, causing more than half a million deaths.
Ric N. Price, Whitty, Christopher J M, Ansah, Evelyn K., Christopher J. M. Whitty, Beeson, James G, Lorenz von Seidlein, Dondorp, Arjen M., Osier, F, Greenwood, Brian, Whitty, CJ, Greenwood, Brian Mellor, Freya J.I. Fowkes, Hemingway, Janet, Beeson, JG, Osier, Faith H A, Seidlein, Lorenz Von, von Seidlein, L, Whitty, Christopher J.M., Fowkes, Freya J.I., Baird, J. Kevin, Greenwood, B, Janet Hemingway, Evelyn K. Ansah, Tanner, M, Fowkes, Freya JI, J. Kevin Baird, Baird, John, Whitty, Christopher J. M., James G. Beeson, von Seidlein, Lorenz, Faith Osier, Price, Richard, Beeson, James G., Fowkes, Freya J. I., Ansah, Evelyn K, Arjen M. Dondorp, Dondorp, AM, Kevin Marsh, Fowkes, Freya J J, Fowkes, FJ, Marcel Tanner, Baird, JK, Whitty, Christopher JM, Fowkes, FJI, Brian Greenwood, Tanner, Marcel, Whitty, CJM, Baird, J Kevin, Ansah, EK, Baird, John Kevin, Dondorp, Arjen M, Marsh, K, Dondorp, Adrianus, Price, Ric N., Ansah, Evelyn Korkor, Price, RN, Hemingway, J, Osier, Faith, Price, Ric N, Marsh, Kevin   +59 more
core   +1 more source

Limited antigenic diversity of Plasmodium falciparumapical membrane antigen 1 supports the development of effective multi-allele vaccines

, 2014
Background: Polymorphism in antigens is a common mechanism for immune evasion used by many important pathogens, and presents major challenges in vaccine development. In malaria, many key immune targets and vaccine candidates show substantial polymorphism.
Drew, Damien R., Anders, Robin, Sheetij Dutta, Cross, Nadia, Senn, Nicolas, Hodder, AN, Dutta, Sheetij, Nicolas Senn, Osier, Faith H. A., Terheggen, Ulrich, Hodder, Anthony, Damien R Drew, Beeson, JG, Nadia J Cross, James G Beeson, Mugyenyi, Cleopatra, Osier, FHA, Alyssa E Barry, Ulrich Terheggen, Hodder, Anthony N., Barry, Alyssa, Siba, Peter, Mueller, I, Siba, PM, Beeson, James, Drew, DR, Stanisic, Danielle I., Terheggen, U, Anders, RF, Beeson, James G., Peter M Siba, Dutta, S, Cross, Nadia J., Stanisic, Danielle, Kevin Marsh, Faith HA Osier, Elliott, Salenna, Barry, AE, Jack S Richards, Anders, Robin F., Barry, Alyssa E., Elliott, Salenna R., Senn, N, Danielle I Stanisic, Stanisic, DI, Mueller, Ivo, Richards, Jack, Ivo Mueller, Marsh, K, Elliott, SR, Richards, Jack S., Drew, Damien, Anthony N Hodder, Mugyenyi, Cleopatra K., Cleopatra K Mugyenyi, Osier, Faith, Richards, JS, Robin F Anders, Cross, NJ, Salenna R Elliott, Marsh, Kevin, Mugyenyi, CK, Siba, Peter M.   +62 more
core   +1 more source

A new malaria vaccination tool based on replication-competent Plasmodium falciparum parasites

EMBO Molecular Medicine
Recently licensed subunit vaccines represent the first and, thus far, the only approved agents for vaccination against malaria. However, these vaccines still fail to confer highly effective long-lasting protective immunity.
Diana Moita, Miguel Prudêncio
doaj   +1 more source

Safety, immunogenicity and duration of protection of a candidate malaria vaccine in Mozambique / Seguridad, inmunogenicidad y duración de protección del candidato a vacuna contra la malaria en Mozambique [PDF]

, 2011
Malaria, caused by Plasmodium falciparum parasites remains a huge public health problem and a major cause of morbidity and mortality in sub-Saharan Africa, especially among children and infants.
Aide, Pedro Carlos Paulino
core